{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:25:17Z","timestamp":1757611517272,"version":"3.44.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":208,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.ctarc.2025.100974","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T06:42:50Z","timestamp":1753771370000},"page":"100974","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Advances in the management of lung & gastro-intestinal cancers: clinical studies review from ASCO 2022\/2023 annual meetings"],"prefix":"10.1016","volume":"44","author":[{"given":"Hafsa","family":"Elmarrachi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meriem","family":"Andrif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabil","family":"Ismaili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2025.100974_bib0001","doi-asserted-by":"crossref","first-page":"S1417","DOI":"10.1016\/j.annonc.2022.08.051","article-title":"LBA10 Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: codeBreaK 200 phase III study","volume":"33","author":"Johnson","year":"2022","journal-title":"Ann. Oncol."},{"issue":"17_suppl","key":"10.1016\/j.ctarc.2025.100974_bib0002","doi-asserted-by":"crossref","first-page":"LBA3","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA3","article-title":"Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB\u2013IIIA non-small cell lung cancer (NSCLC)","volume":"41","author":"Herbst","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.ctarc.2025.100974_bib0003","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.9007","article-title":"Phase (Ph) 1\/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (Ins20)","author":"Yu","year":"2022","journal-title":"J. Clin. Oncol. [Internet]"},{"issue":"17_suppl","key":"10.1016\/j.ctarc.2025.100974_bib0004","doi-asserted-by":"crossref","first-page":"LBA9009","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA9009","article-title":"Activity of adagrasib (MRTX849) in patients with KRASG12C-mutated NSCLC and active, untreated CNS metastases in the KRYSTAL-1 trial","volume":"40","author":"Sabari","year":"2022","journal-title":"JCO"},{"issue":"7","key":"10.1016\/j.ctarc.2025.100974_bib0005","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1158\/2159-8290.CD-20-1683","article-title":"Mobocertinib (TAK-788): a targeted inhibitor of EGFR Exon 20 insertion mutants in non-small cell lung cancer","volume":"11","author":"Gonzalvez","year":"2021","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.ctarc.2025.100974_bib0006","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.4761","article-title":"Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR Exon 20 insertion\u2013positive metastatic non\u2013small cell lung cancer: a phase 1\/2 open-label nonrandomized clinical trial","volume":"7","author":"Zhou","year":"2021","journal-title":"JAMA Oncol."},{"issue":"538","key":"10.1016\/j.ctarc.2025.100974_bib0007","first-page":"56","article-title":"Les mutations de KRAS dans les cancers pulmonaires non \u00e0 petites cellules, opportunit\u00e9s th\u00e9rapeutiques et nouveaux challenges pour le pathologiste","volume":"2022","author":"Lant\u00e9ri","year":"2022","journal-title":"Rev. Francoph. Lab."},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2025.100974_bib0008","doi-asserted-by":"crossref","first-page":"9001","DOI":"10.1200\/JCO.2022.40.16_suppl.9001","article-title":"Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis","volume":"40","author":"Nakajima","year":"2022","journal-title":"JCO"},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2025.100974_bib0009","doi-asserted-by":"crossref","first-page":"8508","DOI":"10.1200\/JCO.2022.40.16_suppl.8508","article-title":"Two-year update from KEYNOTE-799: pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC","volume":"40","author":"Reck","year":"2022","journal-title":"JCO"},{"issue":"17_suppl","key":"10.1016\/j.ctarc.2025.100974_bib0010","doi-asserted-by":"crossref","first-page":"LBA8507","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA8507","volume":"40","author":"Rudin","year":"2022","journal-title":"JCO"},{"issue":"6","key":"10.1016\/j.ctarc.2025.100974_bib0011","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"9","key":"10.1016\/j.ctarc.2025.100974_bib0012","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.3390\/cancers12092584","article-title":"Adjuvant chemotherapy for stage II colon cancer","volume":"12","author":"Rebuzzi","year":"2020","journal-title":"Cancers. (Basel)"},{"issue":"35","key":"10.1016\/j.ctarc.2025.100974_bib0013","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1200\/JCO.2015.63.4238","article-title":"Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study","volume":"33","author":"Andr\u00e9","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100974_bib0014","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3109\/0284186X.2014.975839","article-title":"Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature","volume":"54","author":"B\u00f6ckelman","year":"2015","journal-title":"Acta Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2025.100974_bib0015","article-title":"Adjuvant therapy for completely resected stage II colon cancer","volume":"2008","author":"Figueredo","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"issue":"10","key":"10.1016\/j.ctarc.2025.100974_bib0016","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","article-title":"Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Argil\u00e9s","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2025.100974_bib0017","first-page":"1","article-title":"Treatment of patients with early-stage colorectal cancer: ASCO resource-stratified guideline","volume":"5","author":"Costas-Chavarri","year":"2019","journal-title":"J. Glob. Oncol."},{"issue":"25","key":"10.1016\/j.ctarc.2025.100974_bib0018","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1200\/JCO.2010.34.3426","article-title":"Adjuvant chemotherapy for stage II colon cancer with poor prognostic features","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100974_bib0019","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ijc.30053","article-title":"Adjuvant chemotherapy is not associated with improved survival for all high-risk factors in stage II colon cancer","volume":"139","author":"Verhoeff","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ctarc.2025.100974_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.943253","article-title":"Circulating tumor DNA as a cancer biomarker: an overview of biological features and factors that may impact on ctDNA analysis","volume":"12","author":"S\u00e1nchez-Herrero","year":"2022","journal-title":"Front. Oncol."},{"issue":"18","key":"10.1016\/j.ctarc.2025.100974_bib0021","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2025.100974_bib0022","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s43018-019-0011-0","article-title":"Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small cell lung cancer","volume":"1","author":"Moding","year":"2020","journal-title":"Nat. Cancer"},{"issue":"24","key":"10.1016\/j.ctarc.2025.100974_bib0023","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"17_suppl","key":"10.1016\/j.ctarc.2025.100974_bib0024","doi-asserted-by":"crossref","first-page":"LBA100","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA100","article-title":"Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: the randomized DYNAMIC trial","volume":"40","author":"Tie","year":"2022","journal-title":"JCO"},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2025.100974_bib0025","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1200\/JCO.2022.40.16_suppl.3500","article-title":"Perioperative chemotherapy with mFOLFOX6 or CAPOX for patients with locally advanced colon cancer (OPTICAL): a multicenter, randomized, phase 3 trial","volume":"40","author":"Hu","year":"2022","journal-title":"JCO"},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2025.100974_bib0026","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1200\/JCO.2022.40.16_suppl.3511","article-title":"Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: final clinical analysis of the NICHE study","volume":"40","author":"Verschoor","year":"2022","journal-title":"JCO"},{"issue":"17_suppl","key":"10.1016\/j.ctarc.2025.100974_bib0027","doi-asserted-by":"crossref","first-page":"LBA3505","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA3505","article-title":"Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI\/PAN) versus mFOLFOX6\/PAN as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer (mCRC): results of the phase III randomized TRIPLETE study by GONO","volume":"40","author":"Cremolini","year":"2022","journal-title":"JCO"},{"issue":"12","key":"10.1016\/j.ctarc.2025.100974_bib0028","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1093\/annonc\/mdf337","article-title":"Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity","volume":"13","author":"Xu","year":"2002","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2025.100974_bib0029","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"17_suppl","key":"10.1016\/j.ctarc.2025.100974_bib0030","doi-asserted-by":"crossref","first-page":"LBA3506","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA3506","article-title":"FOLFOXIRI + bevacizumab versus FOLFOX\/FOLFIRI + bevacizumab in patients with initially unresectable colorectal liver metastases (CRLM) and right-sided and\/or RAS \/BRAFV600E- mutated primary tumor: phase III CAIRO5 study of the Dutch Colorectal Cancer Group","volume":"40","author":"Punt","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.ctarc.2025.100974_bib0031","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1","article-title":"Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): results from the phase 3 PARADIGM trial","author":"Yoshino","year":"2022","journal-title":"J. Clin. Oncol. [Internet]"},{"issue":"18","key":"10.1016\/j.ctarc.2025.100974_bib0032","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.3390\/cancers14184453","article-title":"The Evolving landscape of immunotherapy in locally advanced rectal cancer patients","volume":"14","author":"Germani","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"17_suppl","key":"10.1016\/j.ctarc.2025.100974_bib0033","doi-asserted-by":"crossref","first-page":"LBA","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA5","article-title":"Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer","volume":"40","author":"Cercek","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.ctarc.2025.100974_bib0034","article-title":"Dostarlimab: a breakthrough in the field of oncology","volume":"80","author":"Hussain","year":"2022","journal-title":"Ann. Med. Surg. (Lond)"},{"issue":"18","key":"10.1016\/j.ctarc.2025.100974_bib0035","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1200\/JCO.20.03614","article-title":"Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial","volume":"39","author":"Eyck","year":"2021","journal-title":"JCO"},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2025.100974_bib0036","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2022.40.16_suppl.4015","article-title":"Preoperative chemoradiation (CRT) with carboplatin (CBP)\/paclitaxel (PCL) (CP) or with 5-fluorouracil (FU)\/oxaliplatin (OX) (Fx) for esophageal or junctional cancer: a randomized phase 2 trial","volume":"40","author":"Adenis","year":"2022","journal-title":"JCO"},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2025.100974_bib0037","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1200\/JCO.2022.40.16_suppl.4008","article-title":"Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: first results of the CONKO-007 trial","volume":"40","author":"Fietkau","year":"2022","journal-title":"JCO"},{"issue":"2","key":"10.1016\/j.ctarc.2025.100974_bib0038","doi-asserted-by":"crossref","first-page":"C540","DOI":"10.1152\/ajpcell.00331.2022","article-title":"Barriers and opportunities for gemcitabine in pancreatic cancer therapy","volume":"324","author":"Beutel","year":"2023","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ctarc.2025.100974_bib0039","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA4011","article-title":"Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: a prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial","author":"Qin","year":"2022","journal-title":"J. Clin. Oncol. [Internet]"},{"issue":"9","key":"10.1016\/j.ctarc.2025.100974_bib0041","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1200\/JCO.23.00795","article-title":"Gemcitabine and paclitaxel versus gemcitabine alone after 5-fluorouracil, oxaliplatin, and irinotecan in metastatic pancreatic adenocarcinoma: a randomized phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER study","volume":"42","author":"De La Fouchardi\u00e8re","year":"2024","journal-title":"JCO"},{"issue":"21","key":"10.1016\/j.ctarc.2025.100974_bib0042","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJM198011203032101","article-title":"Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma","volume":"303","author":"Moertel","year":"1980","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ctarc.2025.100974_bib0043","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1056\/NEJM199202203260804","article-title":"Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma","volume":"326","author":"Moertel","year":"1992","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ctarc.2025.100974_bib0044","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-06-2053","article-title":"Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors","volume":"13","author":"Ekeblad","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100974_bib0045","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/1078-0432.CCR-08-1476","article-title":"O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors","volume":"15","author":"Kulke","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100974_bib0046","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000225389","article-title":"Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors","volume":"90","author":"Maire","year":"2009","journal-title":"Neuroendocrinology."},{"key":"10.1016\/j.ctarc.2025.100974_bib0047","first-page":"1919","article-title":"Metronomic capecitabine in gastroenteropancreatic neuroendrocrine tumors: a suitable regimen and review of the literature","volume":"7","author":"Bongiovanni","year":"2014","journal-title":"Onco Targets. Ther."},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2025.100974_bib0048","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1200\/jco.2005.23.16_suppl.4216","article-title":"Effective treatment of neuroendocrine tumors with temozolomide and capecitabine","volume":"23","author":"Fine","year":"2005","journal-title":"JCO"},{"issue":"7","key":"10.1016\/j.ctarc.2025.100974_bib0049","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/bjc.2011.76","article-title":"Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours","volume":"104","author":"Medley","year":"2011","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.ctarc.2025.100974_bib0050","first-page":"1461","article-title":"Depletion of O6-methylguanine-DNA methyltransferase by O6-benzylguanine enhances 5-FU cytotoxicity in colon and oral cancer cell lines","volume":"17","author":"Murakami","year":"2007","journal-title":"Oncol. Rep."},{"issue":"2","key":"10.1016\/j.ctarc.2025.100974_bib0051","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cncr.25425","article-title":"First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas","volume":"117","author":"Strosberg","year":"2011","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.ctarc.2025.100974_bib0052","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1200\/JCO.22.01013","article-title":"Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211)","volume":"41","author":"Kunz","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.ctarc.2025.100974_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2023.103449","article-title":"The dual role of DNA repair protein MGMT in cancer prevention and treatment","volume":"123","author":"Bai","year":"2023","journal-title":"DNA Repair (Amst.)"},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2025.100974_bib0054","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1200\/JCO.2022.40.16_suppl.4022","article-title":"Sequential nab -paclitaxel\/gemcitabine followed by modified FOLFOX for first-line metastatic pancreatic cancer: the SEQUENCE trial","volume":"40","author":"Carrato","year":"2022","journal-title":"JCO"},{"issue":"9","key":"10.1016\/j.ctarc.2025.100974_bib0055","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.ctarc.2025.100974_bib0056","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2606","volume":"34","author":"Vogel","year":"2023","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1016\/j.ctarc.2025.100974_bib0057","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s11523-023-01007-y","article-title":"Durvalumab: a review in advanced biliary tract cancer","volume":"18","author":"Fung","year":"2023","journal-title":"Target. Oncol."},{"issue":"8","key":"10.1016\/j.ctarc.2025.100974_bib0058","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM. Evid."},{"issue":"5","key":"10.1016\/j.ctarc.2025.100974_bib0059","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1002\/hep.30482","article-title":"Tremelimumab in combination with microwave ablation in patients with refractory biliary tract cancer","volume":"69","author":"Xie","year":"2019","journal-title":"Hepatology"},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2025.100974_bib0060","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.1200\/JCO.2022.40.16_suppl.4108","article-title":"Durvalumab (D) plus tremelimumab (T) immunotherapy in patients (Pts) with advanced biliary tract carcinoma (BTC) after failure of platinum-based chemotherapy (CTx): interim results of the IMMUNOBIL GERCOR D18-1 PRODIGE-57 study","volume":"40","author":"Delaye","year":"2022","journal-title":"JCO"},{"issue":"3","key":"10.1016\/j.ctarc.2025.100974_bib0061","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.ctarc.2025.100974_bib0062","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100974_bib0063","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100974_bib0064","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.ctarc.2025.100974_bib0065","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update","volume":"11","author":"Omata","year":"2017","journal-title":"Hepatol. Int."},{"issue":"5","key":"10.1016\/j.ctarc.2025.100974_bib0066","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/SLA.0b013e3181a38eb5","article-title":"Predictors of survival after resection of early hepatocellular carcinoma","volume":"249","author":"Nathan","year":"2009","journal-title":"Ann. Surg."},{"issue":"6","key":"10.1016\/j.ctarc.2025.100974_bib0067","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S2468-1253(18)30078-5","article-title":"Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial","volume":"3","author":"Kudo","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"10","key":"10.1016\/j.ctarc.2025.100974_bib0068","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.22.01142","article-title":"Postoperative adjuvant hepatic arterial infusion chemotherapy with FOLFOX in hepatocellular carcinoma with microvascular invasion: a multicenter, phase III, randomized study","volume":"41","author":"Li","year":"2023","journal-title":"JCO"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225001108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225001108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T21:18:06Z","timestamp":1756934286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294225001108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":67,"alternative-id":["S2468294225001108"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.100974","relation":{},"ISSN":["2468-2942"],"issn-type":[{"type":"print","value":"2468-2942"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the management of lung & gastro-intestinal cancers: clinical studies review from ASCO 2022\/2023 annual meetings","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.100974","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100974"}}